Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
2014-004587-38Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of esketamine in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in Bladder Pain/Interstitial Cystitis Symptom. Started Jul 2015; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2014-004587-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004587-38.